Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Healthy Alaskan.
Press releases published on May 5, 2025
MicroRNAs Research Initiative in Glioblastoma Stem Cells Awarded $85K by Brain Cancer Canada
GlobeNewswire
·
May 5, 2025
TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is pleased to announce a $85,000 grant for a cutting-edge research initiative led by Dr. Leonardo Salmena at the University of Toronto. The project, titled “Exploring microRNA as Targets for …
CareSource and Lakeland Care, Inc. pursue affiliation to enhance long-term services and supports offerings across Wisconsin
GlobeNewswire
·
May 5, 2025
DAYTON, Ohio and FOND du LAC, Wis., May 05, 2025 (GLOBE NEWSWIRE) -- CareSource, a nationally recognized nonprofit managed care organization, and Lakeland Care, Inc., a leading Wisconsin-based managed care provider, have announced their intent to pursue an …
LainaHealth Launches Clinician + WebAI Care Model to Redefine Physical Therapy Access and Affordability
GlobeNewswire
·
May 5, 2025
Columbus, OH, May 05, 2025 (GLOBE NEWSWIRE) -- LainaHealth, formerly IncludeHealth, announced today the launch of its transformative virtual care model that pairs licensed physical therapists with Laina, a proprietary WebAI assistant, to significantly …
NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025
GlobeNewswire
·
May 5, 2025
CARMEL, Ind., May 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults …
Cannabix Technologies Receives NHTSA Approval for BreathLogix Workplace Series Alcohol Breathalyzer
GlobeNewswire
·
May 5, 2025
VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports that it has received notice from the U.S. National Highway Traffic Safety Association …
Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents
GlobeNewswire
·
May 5, 2025
Company continues to expand global IP coverage and claims to major markets, now extending to June 2040 HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company …
Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain
GlobeNewswire
·
May 5, 2025
Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care Patient testimonial now available here THE WOODLANDS, TX, May 05, 2025 (GLOBE NEWSWIRE) -- …
MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)
GlobeNewswire
·
May 5, 2025
MARIETTA, Ga., May 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of its health economics data for reconstruction of cutaneous wounds with EPIFIX® (Dehydrated Human Amnion Chorion …
SS Innovations Reiterates Guidance for First Quarter 2025 and Provides Commentary on Second Quarter 2025 Order Trends
GlobeNewswire
·
May 5, 2025
FORT LAUDERDALE, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and …
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock
GlobeNewswire
·
May 5, 2025
HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the pricing of an underwritten public offering …
Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025
GlobeNewswire
·
May 5, 2025
LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally …
IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025
GlobeNewswire
·
May 5, 2025
LAWRENCEVILLE, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. ET on Monday, …
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025
GlobeNewswire
·
May 5, 2025
SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Monday, May …
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
GlobeNewswire
·
May 5, 2025
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates
GlobeNewswire
·
May 5, 2025
UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the …
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
GlobeNewswire
·
May 5, 2025
CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent corporate updates. Three Months Ended …
Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
GlobeNewswire
·
May 5, 2025
Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1 Mature overall survival data builds on encouraging high response rates with multiple complete …
Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
GlobeNewswire
·
May 5, 2025
Builds upon Firefly’s recent acceptance into the NVIDIA Connect program Marks next major step toward building a proprietary foundation model of the human brain KENMORE, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “ …
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 5, 2025
—Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now expects to be profitable for full year 2025, a year ahead of schedule— —Company pays down …
Regeneration Biomedical to Present Updated Phase 1 Trial Data on Autologous Stem Cell Therapy Injected Directly into the Brain for Alzheimer’s Disease in Podium Presentation at the ISCT 2025 Scientific Annual Meeting
GlobeNewswire
·
May 5, 2025
Abstract selected for a podium presentation and winner of the Host Region (US West) Award First-in-human data now includes five patients, with follow-up ranging from 23 weeks to over a year post-treatment Injections of Wnt-activated, autologous, expanded, …